$0.00
0.00%
Nasdaq, Thu, Aug 07 2025
ISIN
NL0010872420
Symbol
AFMD

Affimed N.V. Stock price

$0.00
-0.04 99.73% 1M
-1.05 99.99% 6M
-1.19 99.99% YTD
-4.39 100.00% 1Y
-32.80 100.00% 3Y
-38.10 100.00% 5Y
-132.20 100.00% 10Y
-57.00 100.00% 20Y
Nasdaq, Closing price Thu, Aug 07 2025
+0.00 0.00%
ISIN
NL0010872420
Symbol
AFMD
Industry

Key metrics

Basic
Market capitalization
$380.0k
Enterprise Value
$-12.7m
Net debt
positive
Cash
$28.1m
Shares outstanding
16.4m
Valuation (TTM | estimate)
P/E
0.0 | 0.0
P/S
0.4 | 0.2
EV/Sales
negative | negative
EV/FCF
0.1
P/B
0.0
Financial Health
Equity Ratio
59.5%
Return on Equity
-183.3%
ROCE
-302.8%
ROIC
-1,173.4%
Debt/Equity
0.7
Financials (TTM | estimate)
Revenue
$1.0m | $2.1m
EBITDA
$-77.9m | $-141.6m
EBIT
$-81.9m | $-75.7m
Net Income
$-81.6m | $-79.6m
Free Cash Flow
$-90.3m
Growth (TTM | estimate)
Revenue
-95.4% | -78.8%
EBITDA
40.8% | -14.0%
EBIT
39.4% | 39.7%
Net Income
41.3% | 35.6%
Free Cash Flow
35.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-7,615.2% | -6,904.4%
EBIT
-8,005.3%
Net
-7,978.3% | -3,879.9%
Free Cash Flow
-8,829.9%
More
EPS
$-5.1
FCF per Share
$-5.5
Short interest
3.8%
Employees
76
Rev per Employee
$130.0k
Show more

Is Affimed N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Affimed N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Affimed N.V. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Affimed N.V. forecast:

Buy
90%
Hold
10%

Financial data from Affimed N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.02 1.02
95% 95%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
30% 30%
2,161%
- Research and Development Expense 61 61
52% 52%
5,982%
-78 -78
41% 41%
-7,638%
- Depreciation and Amortization 3.99 3.99
10% 10%
391%
EBIT (Operating Income) EBIT -82 -82
39% 39%
-8,030%
Net Profit -82 -82
41% 41%
-8,003%

In millions USD.

Don't miss a Thing! We will send you all news about Affimed N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Affimed N.V. Stock News

Neutral
GlobeNewsWire
3 months ago
MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) notifying the Company that, in accordance with Nasdaq Listing Rule 5101,...
Neutral
GlobeNewsWire
3 months ago
MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany.
Neutral
GlobeNewsWire
3 months ago
MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager (ICE®) AFM24, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) in a poster session at the 2...
More Affimed N.V. News

Company Profile

Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Head office Netherlands
CEO Shawn Leland
Employees 76
Founded 2000
Website www.affimed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today